FDA approves Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog for glycemic control in adult and pediatric diabetes patients, expanding treatment accessibility.
A Connecticut psychiatrist agreed to a $455K settlement after an investigation identified fraudulent Medicare claims and unsafe controlled substance prescribing practices, resulting in DEA sanctions and a 20-year exclusion from federal health programs.
SGLT-2 inhibitors and GLP-1 receptor agonists were associated with a reduced risk of moderate or severe COPD exacerbations compared with DPP-4 inhibitors in adults with type 2 diabetes.